Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer | Zendy

Dana E. Rathkopf | Zendy; Michael J. Morris | Zendy; Josef J. Fox | Zendy; Daniel C. Danila | Zendy; Susan F. Slovin | Zendy; Jeffrey H. Hager | Zendy; Peter J. Rix | Zendy; Edna Chow Maneval | Zendy; Isan Chen | Zendy; Mithat Gönen | Zendy; Martin Fleisher | Zendy; Steven M. Larson | Zendy; Charles L. Sawyers | Zendy; Howard I. Scher | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer

Author(s) -

Dana E. Rathkopf,

Michael J. Morris,

Josef J. Fox,

Daniel C. Danila,

Susan F. Slovin,

Jeffrey H. Hager,

Peter J. Rix,

Edna Chow Maneval,

Isan Chen,

Mithat Gönen,

Martin Fleisher,

Steven M. Larson,

Charles L. Sawyers,

Howard I. Scher

Publication year - 2013

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2013.50.1684

Subject(s) - medicine , tolerability , pharmacokinetics , prostate cancer , pharmacodynamics , antiandrogen , adverse effect , bicalutamide , urology , pharmacology , androgen receptor , context (archaeology) , androgen deprivation therapy , cancer , paleontology , biology

ARN-509 is a novel androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (CRPC). ARN-509 inhibits AR nuclear translocation and AR binding to androgen response elements and, unlike bicalutamide, does not exhibit agonist properties in the context of AR overexpression. This first-in-human phase I study assessed safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of ARN-509 in men with metastatic CRPC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research